UAEM - Licensing and patenting practices of UK research institutions 2019-2020

Sarai Keestra made this Freedom of Information request to University of Bristol

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

The request was successful.

Dear University of Bristol,

We have previously sent FOI requests asking for information about the licensing practices of UK universities. This was concerning the time period 18th October 2018 to 18th October 2019. We are now looking to update the information for the following year, 19th October 2019 to 19th October 2020.

The updated request is listed below:
For the purpose of clarity, please adhere to the following definitions when answering these questions:

Definitions
Low and middle income country: A country that is defined as ‘low’, ‘lower-middle’ and ‘upper-middle’ income by the World Bank for the year 2018. Income status defined by GNI per capita.
Source: World bank, available online [https://tinyurl.com/y5dwc2qv]

A patent grants an inventor the exclusive rights to his or her invention. A patent holder can stop other people from selling, manufacturing, producing, or using the invention for a certain period of time.
Source: Upcouncil, available online [https://www.upcounsel.com/what-is-a-pate...
Licence: Permission for the licensee to use the intellectual property rights
Source: TaylorWessing, available online [https://www.taylorwessing.com/download/a...

Exclusive Licence: A licence that allows only the named licensee to exploit the relevant IP rights, the licensor is also excluded from exploiting these IP rights.
Non-Exclusive Licence: A licence that grants any number of licensees to exploit the IP.
Source: TaylorWessing, available online [https://www.taylorwessing.com/synapse/co...

Health Technology: ‘Health technology as defined by the WHO: “A health technology is the application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and improve quality of lives.’
Source: WHO, available online [https://www.who.int/health-technology-as...

START FOI request:
Q1. Has the university committed to licensing its medical discoveries in ways that promote access and affordability in Low- and Middle- Income Countries? If yes, please provide a link or PDF to the relevant policy document.

Q2. Please provide an Excel spreadsheet with headings as displayed below with all the health technologies LICENSED by the university in the period 19th October 2019 to 19th October 2020 AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.
Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)

Q3. Please provide a list of patents granted to your organization in the period 19th October 2019 to 19th October 2020, listed by patent family, indicating countries/regions in which the patent has been granted.

Q4. In the period 19th October 2019 to 19th October 2020, has the university shared its best practices for promoting access to medicines through non-exclusive licensing by carrying out any of the following activities?

❏ Contributed sample clauses to the AUTM Global Health Toolkit
❏ Published an article, guidance, or other literature on access licensing practices
❏ Formally presented on access licensing practices at an academic or professional event, or at another university
❏ Informally shared or discussed access licensing practices with administrators at other universities
❏ Other
❏ None
(Tick as appropriate)

Q5. What actions has the technology transfer office (TTO) undertaken in the period 19th October 2019 to 19th October 2020 to improve access to the technologies they license in low-and middle-income settings?

END FOI request.
If you have any questions please do not hesitate to contact me by email.

Yours faithfully,

Sarai Keestra

University of Bristol FOI mailbox, University of Bristol

Thank you for your e-mail. The University will endeavour to respond to
your request under the Freedom of Information Act within 20 working days.

However, please note that due to the current Covid-19 pandemic, there may
be unavoidable delays in responding to your request. We would be grateful
if you could bear with us if we are unable to respond within the statutory
time-frame, and we apologise for any inconvenience that this may cause.

We may need to ask you certain questions to clarify your request to ensure
we fully understand what information is being requested. If so, the 20
working day deadline will be calculated once we have received such
clarification. 

 

The University's A-Z index can help in locating information that is
publicly available on the University's
website: [1]http://www.bristol.ac.uk/index/

 

Our Publication Scheme is available
at: [2]http://www.bristol.ac.uk/media-library/s...

 

The Higher Education Statistics Agency (HESA) annually publish certain
data about students and higher education: [3]https://www.hesa.ac.uk/.
Bespoke datasets can be requested from
Jisc: [4]https://www.jisc.ac.uk/tailored-datasets.

 

For further information about the University's FOI procedure, please
see: [5]http://www.bristol.ac.uk/secretary/foi/

References

Visible links
1. http://www.bristol.ac.uk/index/
2. http://www.bristol.ac.uk/media-library/s...
3. https://www.hesa.ac.uk/
4. https://www.jisc.ac.uk/tailored-datasets
5. http://www.bristol.ac.uk/secretary/foi/

SecOInformation Governance, University of Bristol

Dear Ms Keestra

 

Freedom of Information Request (our reference FOI20549)

 

We refer to your Freedom of Information request dated 10 November 2020.
You requested information regarding licensing of medical discoveries by
the University of Bristol.

 

University’s Response

 

Further to Section 1 of the Freedom of Information Act 2000 (the “Act”) we
confirm that the information requested is held by the University of
Bristol (the “University”).

 

1.      Has the university committed to licensing its medical discoveries
in ways that promote access and affordability in Low- and Middle- Income
Countries? If yes, please provide a link or PDF to the relevant policy
document.

 

Yes. Please see the University’s Humanitarian Medical IP Commercialisation
policy:
[1]www.bristol.ac.uk/media-library/sites/red/migrated/documents/ems.pdf.
You can also find more information about the University’s approach to
commercialisation of its medical discoveries here:
[2]https://www.bristol.ac.uk/business/resea....

2.      Please provide an Excel spreadsheet with headings as displayed
below with all the health technologies LICENSED by the university in the
period 19th October 2019 to 19th October 2020 AND specify which countries
they were licensed in AND specify whether they are exclusive or
non-exclusive licenses.
Health Technology Licensed; Country of Licensing; Type of License
(Exclusive or Non-Exclusive)

Please see table below.

 

Country of Type of
Health technology licensed Licensing Licence
cell line for drug development R&D Worldwide Non-Exclusive
cell line for drug development R&D Worldwide Non-Exclusive
cell line for drug development R&D Worldwide Non-Exclusive
cell line for drug development R&D Worldwide Non-Exclusive
cell line for drug development R&D Worldwide Non-Exclusive
virus isolates for antiviral R&D Worldwide Non-Exclusive
Jointly owned IP on antiviral therapeutic target Worldwide Exclusive
Jointly owned IP on bacterial identification
technology Worldwide Assignment
Jointly owned IP on pharmaceutical synthesis
route Worldwide Assignment
Pharmaceutical synthesis route Worldwide Assignment

 

3.      Please provide a list of patents granted to your organization in
the period 19th October 2019 to 19th October 2020, listed by patent
family, indicating countries/regions in which the patent has been granted.

 

Please see table below.

 

Health technology patent granted Territory of patent
Biologic for inflammatory disease UK
Biologic for inflammatory disease France
Biologic for inflammatory disease Germany
Probiotic for inflammatory disease Austria
Probiotic for inflammatory disease Switzerland
Probiotic for inflammatory disease Germany
Probiotic for inflammatory disease Spain
Probiotic for inflammatory disease France
Probiotic for inflammatory disease United Kingdom
Probiotic for inflammatory disease Ireland
Probiotic for inflammatory disease Italy
Cellular bandage for tissue repair US

 

 

4.      In the period 19th October 2019 to 19th October 2020, has the
university shared its best practices for promoting access to medicines
through non-exclusive licensing by carrying out any of the following
activities?

a.      Contributed sample clauses to the AUTM Global Health Toolkit

b.      Published an article, guidance, or other literature on access
licensing practices

c.       Formally presented on access licensing practices at an academic
or professional event, or at another university

d.      Informally shared or discussed access licensing practices with
administrators at other universities - Yes

e.      Other

f.        None

 

The University has informally shared or discussed access licensing
practices with administrators at other universities.

 

5.      What actions has the technology transfer office (TTO) undertaken
in the period 19th October 2019 to 19th October 2020 to improve access to
the technologies they license in low-and middle-income settings?”

 

The University has continued to ensure that clauses to incentivise
provision of access to the technologies it licences in low- and middle-
income countries are included in its licensing terms for health
technology. 

 

Internal Review Procedure

 

If you are dissatisfied with the handling of your request, then you have a
right under Section 50 of the Act to request an internal review.  All such
requests must be sent to us within 40 days, clearly stating your reason
for requesting an internal review.  We will aim to respond to your request
for an internal review within 20 working days of receipt.

 

Your request for an internal review should be sent to
[University of Bristol request email], quoting our FOI reference number (see
above). Alternatively, you could post it to:

 

Director of Legal Services

Secretary’s Office

University of Bristol

Beacon House

Queens Road

Bristol

BS8 1QU

 

Information Commissioners Office

 

Should you remain dissatisfied with the final outcome of the internal
review then you may apply directly to the Information Commissioner (the
“ICO”) for an independent review.  The ICO is the Government’s Independent
Body responsible for overseeing the Freedom of Information Act 2000, the
Data Protection Act 2018 and The Environmental Information Regulations
2004.

 

Please note the ICO will only review cases that have exhausted the
University’s internal review procedure. All correspondence to the ICO must
quote the University’s reference number and your reasons for your appeal. 
The ICO’s contact details are as follows:

 

The Information Commissioners Office

Wycliffe House

Water Lane

Wilmslow

Cheshire

SK9 5AF

 

More information can be found on the ICO’s website
at [3]http://www.ico.org.uk

 

Kind Regards

 

Freedom of Information Team

University of Bristol

 

 

References

Visible links
1. http://www.bristol.ac.uk/media-library/s...
2. https://www.bristol.ac.uk/business/resea...
3. http://www.ico.org.uk/